We collect as much information and data as we can find about a problem and potential solutions. We focus on the successes but most importantly we focus on the failures that others have experienced. To us a failure is nothing but a solution waiting for a problem. If a solution does not fit or is lacking, then we begin to design a better solution.

Why Data Collection & Failure Analysis are Critical to Biotech

Our philosophy—“a failure is nothing but a solution waiting for a problem”—is exactly how the most disruptive breakthroughs in modern biotechnology are born. In biotech, a failed clinical trial or an abandoned molecule is rarely a dead end; it is a highly valuable data point that simply lacked the right context, the right patient subpopulation, or the right delivery mechanism.

Rigorous data collection and research are the bedrock of defining a biological problem. Without them, scientists risk designing brilliant solutions for the wrong cellular targets.

Defining a problem in biotech is uniquely difficult because biology is non-linear, adaptive, and highly complex. Collecting exhaustive data—especially “negative data” (failures)—is critical for three reasons:

De-risking the “Hypothesis Trap”:

Human researchers often fall into confirmation bias, focusing heavily on successful published papers. However, 90% of translational biotech research fails. By exhaustively collecting data on why previous solutions failed (e.g., toxicity, poor bioavailability, or off-target effects), you define the exact boundaries of the problem you need to solve.

Finding the “Missing Context” for Abandoned Solutions:

Many historic drugs failed not because the molecule was bad, but because the technology of the time couldn’t deliver it properly, or because the drug was tested on the wrong patient population.

Turning Structural Flaws into Design Specifications:

When we analyze a failed solution and find exactly where it is lacking, those deficiencies become the strict engineering parameters for our new design.

The Evolution of Data Collection and Research

AI has fundamentally changed how biotech companies aggregate, read, and exploit both successful and failed scientific data.

Era	How Data is Collected & Researched	How “Failure Data” is Handled	The Role of AI / Technology
The Manual Era (Pre-2010s)	Researchers manually read peer-reviewed journals, static spreadsheets, and textbook databases. Data collection was slow, siloed, and limited by human reading speed.	Hidden and lost. Negative results and failed trials were rarely published in journals. Failed internal pharma data sat forgotten in legacy corporate silos.	Basic Digitization: Keyword search engines (e.g., early PubMed) and static relational databases.
The Omics Big Data Era (2010s–Early 2020s)	High-throughput sequencing generated massive datasets (genomics, proteomics). Data collection became vast but highly fragmented and unorganized.	Overwhelming noise. Millions of data points on failures existed in public repositories, but humans lacked the computational power to connect the dots across different biological layers.	Bioinformatics & Analytics: Traditional machine learning algorithms used for clustering data, statistical pattern recognition, and basic gene-mapping.
The Generative & Agentic Era (Today, 2026)	Autonomous Knowledge Graphs: AI agents ingest millions of data points simultaneously—including text, molecular structures, clinical trial notes, patents, and raw lab data.	Systematically mined. Generative AI models deliberately hunt for “dark data” and failed clinical trials to understand exactly why a mechanism broke down, turning past failures into immediate design constraints.	Multimodal Foundation Models & LLMs: Scientific AI models (like specialized variants of AlphaFold 3 and BioBERT) that read, reason, and simulate biological systems to predict failures before wet-lab testing.

How AI Transforms “Failures” into Novel Solutions

Using our framework—treating a failure as a solution waiting for the right problem—modern AI tools execute this workflow at scale through three main capabilities:

1. Ingesting “Dark Data” and Unstructured Texts

Much of the world’s failure data is trapped inside unstructured formats: PDF lab notebooks, patent applications, and supplementary data sections. Large Language Models (LLMs) trained specifically on chemistry and biology can ingest millions of these documents. They extract hidden correlations, such as a molecule that failed as a cancer drug but showed an unintended, highly potent effect on an isolated immune pathway—effectively matching an old “failed” solution to a brand new problem.

2. Virtual Screens of Failed Clinical Trials

AI platforms can recreate past, failed clinical trials in virtual environments. By overlaying the trial data with modern single-cell RNA sequencing and patient multi-omics, the AI can discover that a “failed” drug actually worked perfectly for a tiny, specific 5% subset of patients with a rare genetic biomarker. AI rescues the failure by redefining the problem as a niche, precision-medicine opportunity rather than a broad-market drug.

3. Generative “Reverse Engineering”

When our research identifies that a past solution is lacking (e.g., an antibody binds to the right disease target but causes toxic side effects), generative AI algorithms can hold the successful binding mechanism completely steady while completely redesigning the rest of the molecular backbone. The AI uses the failure as a blueprint, keeping what worked and mutating what failed until a optimized, novel solution is generated.

Data Collection & Research